BG
DFTX

Bellevue Group’s Definium Therapeutics DFTX Stock Holding History

Bellevue Group’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$395K Buy
+8,391
New +$207K 0.01% 116

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Bellevue Group's DFTX Position: Q2 2026 in Review

Bellevue Group opened a new position in Definium Therapeutics (DFTX) in Q2 2026: 8,391 shares worth $395K. The stake represents 0.01% of the portfolio and ranks #116 among its holdings.

319 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • Bellevue Group held 8,391 shares of Definium Therapeutics worth $395K as of Q2 2026.
  • Definium Therapeutics was a new Bellevue Group position in Q2 2026.
  • Definium Therapeutics made up 0.01% of Bellevue Group's portfolio in Q2 2026, its #116 holding.
  • 319 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Bellevue Group's 13F filing for Q2 2026, filed 14 Aug 2026.